LYKALABS vs ORCHPHARMA: Stock Comparison
ORCHID PHARMA is the larger company by market capitalisation. LYKALABS shows a lower P/E and faster revenue growth, while ORCHID PHARMA shows a higher ROE, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
LYKALABS leads 3; ORCHPHARMA leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | LYKALABS | ORCHPHARMA |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | LYKALABS | ORCHPHARMA |
|---|---|---|
| Live Price | ₹74.83 | ₹1,003.05 |
| Day Change | 1.19% | -1.28% |
| Volume | 88,556 | 68,916 |
| 52-Week High | ₹101.9 | ₹1,133 |
| 52-Week Low | ₹44.1 | ₹480 |
| Distance from 52W High | -26.57% | -11.47% |
Valuation
| Metric | LYKALABS | ORCHPHARMA |
|---|---|---|
| Market Cap | ₹298 Cr | ₹5,123 Cr |
| P/E Ratio | 0x | 478.67x |
| P/B Ratio | 2.67x | 3.27x |
| EPS | ₹0.58 | ₹2.35 |
| Book Value | ₹25.12 | ₹308.43 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | LYKALABS | ORCHPHARMA |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | -1.5% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 2.62% | 270.21% |
Profitability & Leverage
| Metric | LYKALABS | ORCHPHARMA |
|---|---|---|
| ROE | -11.49% | 3.3% |
| ROCE | -6.25% | 3.77% |
| Net Margin | -7.81% | 2.51% |
| Operating Margin | -6.71% | 7.2% |
| Debt to Equity | 0.53x | 0.13x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | LYKALABS | ORCHPHARMA |
|---|---|---|
| Promoter Holding | 58.45%▲ 0.29 pp | 69.84% |
| FII Holding | 0.17%▼ 0.12 pp | 0.81%▼ 0.06 pp |
| DII Holding | 0.66%▼ 0.01 pp | 20.75%▲ 0.5 pp |
| Public Holding | 40.72%▼ 0.16 pp | 8.61%▼ 0.44 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: LYKALABS and ORCHID PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.